Overview. Author Summary: Abstract and Brief Discussion
|
|
- Kathlyn Wright
- 6 years ago
- Views:
Transcription
1 Overview First Published Online March 2, 2015 DOI: /theoncologist Title: Pemetrexed and Gemcitabine Versus Carboplatin and Gemcitabine in Non-Small Cell Lung Cancer: A Randomized Noninferiority Phase II Study in One Center Authors: Eva Branden, Gunnar Hillerdal, Karl Kolbeck, Hirsh Koyi Karolinska Hospital, Stockholm, Sweden ClinicalTrials.gov Identifier: Stockholm EU-nr Sponsor(s): Eli Lilly Sweden Principal Investigator: Gunnar Hillerdal IRB Approved: Yes Disclosures The authors indicated no financial relationships. Author Summary: Abstract and Brief Discussion Background The standard treatment for non-small cell lung cancer (NSCLC) stages IIIb and IV is a platinum compound combined with a third-generation cytotoxic agent.we decided to conduct a phase II study to assess whether the platinum compound could be replaced with pemetrexed with similar results and without an increase in side effects. Methods Consecutive eligible patients were randomized to either the standard arm of gemcitabine plus carboplatin (GC) or the experimental arm of gemcitabine plus pemetrexed (GP). Results Fifty evaluable patients were enrolled in the GC arm, and 44 received GP.There were 10 partial responses in the GC arm and 16 in the GP arm.with GC, mean survival was 9 months compared with 15 months with GP.The side effects were similar in both groups. Conclusion Pemetrexed can replace platinum compounds in the first-line treatment of stage IIIb and IV NSCLC without increasing the side effects. A trend toward better survival was observed in the patients receiving pemetrexed instead of a platinum compound, and this should be studied further. Discussion This study was planned to determine whether, in the first-line setting, a platinum compound could be replaced with another cytotoxic agent for the treatment of stage IIIb and IV NSCLC without an increase in toxicity. Encouraging results were obtained, with the combination of gemcitabine and pemetrexed appearing to improve outcome, with more partial responses and longer survival with better tolerability (Fig. 1). Although the schedule of administration was different, doses
2 werechosen to providesimilardose intensityofgemcitabine.the gemcitabinedoseintensitywas 833 mg/m 2 per week in GC and 750 mg/m 2 per week in GP. This minor dose difference is unlikely to explain any difference between the two groups. In conclusion, this study found encouraging results when pemetrexed was substituted for a platinum compound in the firstline treatment of NSCLC without increasing the side effects. A trend toward better survival was observed with the GP combination, but the study was not powered to show this. Further studies with this combination seem warranted. Trial Information Disease Stage of disease / treatment Prior Therapy Type of study - 1 Type of study - 2 Primary Endpoint Additional Details of Endpoints or Study Design Lung cancer NSCLC Metastatic / Advanced None Phase II Randomized Overall Survival After written informed consent, consecutive patients with newly diagnosed stage IIIB or IV NSCLC not suitable for curative treatment (according to TNM classification 6) and performance status (PS) 0 2 were randomized to either gemcitabine plus carboplatin (GC) or pemetrexed plus gemcitabine (PG). All cases had to be cytologically or pathologically confirmed. In the GC arm, treatment was gemcitabine, 1,250 mg/m 2 and carboplatin AUC 5, onday1,and gemcitabine 1,250 mg/m 2 alone on day 8. Cycles were given on a three-week basis and a total of 4 cycles were given. Thus, treatment lasted 84 days, and the total dose of gemcitabine was planned to be 10,000 mg/m 2, provided there was no dose reductions. In the GP arm, treatment consisted of pemetrexed and gemcitabine 1,500 mg/m 2 every 14th day for 6 cycles.thus,treatmentalso lasted 84 days, and the planned total dose ofgemcitabine was 9,000 mg/m 2.The goalwastoadministerasimilartotaldoseofgemcitabine(whichalmost succeeded) over the same time period. All patients in both groups received supplementation treatment with folic acid and vitamin B12. adjustments: With hematologic toxicity, dose reduction was required. If WBC were per liter or platelets perliteratthestartofnextthenextcycle, 75% ofbothdrugsweregiven, and the reduced doses were then continued throughout the rest of the treatment. If WBC at this the start of the next cycle was, per literor platelets, per liter, treatment was withheld one week to allow for further recovery; if this did not happen within 3 weeks, the patientwasexcludedfromthestudy. reductionswerealsomadeif there was leukopenic fever or hemorrhage due to low thrombocytes necessitating hospitalization, and for grade 3 4 nonhematological toxicity except grade 3 alopecia, nausea, and vomiting. Investigations: Evaluation of tumor status was performed using RECIST criteria [1]. Chest x-ray was performed at baseline (less than 4 weeks before start of treatment), halfway through namely, before fourth cycle in the GP and before the third cycle in the GC arm, 2 4 weeks after the last dose of chemotherapy, and then at every follow-up. Follow-up was done every two months until progressive disease occurred. CT scan of the thorax including upper part of the abdomen was performed at baseline, 2 4 weeks after last dose of chemotherapy, and whenever progression was suspected from chest x-ray. St Georges Questionnaire on Qualityof Life was administered at baseline, halfway through, and 2 4 weeks after the last dose of chemotherapy. Hematology investigations were followed weekly as long as the patient received treatment. Statistical considerations: This was a randomized, open label, phase-ii study with the main purpose to investigate the objective response (OR) rate intwo groups of patientswith stage III/IVnon-small cell lung cancer(nsclc). Study patientswere allocatedrandomlytotreatment with gemcitabine plus carboplatin (GC group) or treatment with gemcitabine plus pemetrexed (GP group). The purpose of the design was to compare the obtained OR-rate in each treatment arm with a predetermined rejection level. The study was not powered for a comparison between the two randomization groups.
3 Investigator s Analysis The Simon optimal two-stage design was used to define the number of patients necessary to complete the study. The Simon two-stage design was conducted separately for each randomized arm. The specifications of the design depended on the lowest OR-rates of clinical interest, a target OR-rate and the type I and II error rates. A treatment would be considered to be of no further clinical interest, if the OR-rate was less than or equal to 20% (Ho: OR rate 2%). A treatment would be of definite clinical interest, if the OR-rate was at least 40% (Ha: OR rate 40%).The type I error rate was 5%, which isthe probability ofconcluding that a treatment is active (i.e., rejecting Ho), whereas in reality it is not so.the type II error rate was 20%, which is the probability of concluding that a treatment is inactive (i.e., rejecting Ha), whereas in reality the treatment is active. The number of evaluable patients required in each treatment arm was 13 in the first stage and possibly an additional 30 in the second stage.thetotalnumberofevaluablepatients, ineachgroup, wastobe either 13 or 43. If there were less than 3 patients whose tumor responded to treatment in the first 13 patients, then that treatment armwastobe closedtofurtheraccrualanditwould be concluded that the treatment is not effective (i.e., rejecting Ha). If there were 3 or more responding patients in the first 13 patients, then 30 additional patients would be enrolled in the second stage. At the end of the second stage more than 12 patients with a response of their tumor in 43 were required to reject Ho and conclude that the treatment is of clinical interest in terms of response rate. Otherwise, Ha is rejected, and the treatment will be considered of no further interest. In order to obtain 86 (43 3 2) evaluable patients a minimum number of 96 were planned to be randomized. The patient accrual time was estimated to be 2 years. All randomized patients who received study treatment were included in the safety analysis. Median duration of response, median time to progression and median survivaltimewasestimatedusingthekaplan-meierproductlimitmethod. Ethics committee. The ethics committee of the Karolinska Institute approved the study. Active and should be pursued further Drug Information Drug 1 Pemetrexed Trade name Alimta Company name Eli Lilly 500 mg/m 2 per Schedule of Administration Every 14th day for maximum 6 cycles Drug 2 Carboplatin per Schedule of Administration AUC 5, on a 3-week basis, 4 cycles Drug 3 Gemcitabine per Schedule of Administration 1,250 mg/m 2 on days 1 and 8, 3-week cycles Drug 4 Gemcitabine per Schedule of Administration 1,500 mg/m 2 every 14 days for a total of 9,000 mg/m 2
4 Patient Characteristics Number of patients, male 43 Number of patients, female 57 Stage IIIb and IV Age Median (range): 67 (47 84) Number of prior systemic therapies Median (range): None Performance Status ECOG Unknown Primary Assessment Method Experimental Arm: Total Patient Population Number of patients enrolled 45 Number of patients evaluable for toxicity 44 Number of patients evaluated for efficacy 44 Evaluation method Clinical Response assessment PR 16% Response assessment SD 13% Response assessment PD 15% (Median) duration assessments OS 15 months Control Arm: Total Patient Population Number of patients enrolled 50 Number of patients evaluable for toxicity 49 Number of patients evaluated for efficacy 49 Evaluation method Clinical Response assessment PR 10% Response assessment SD 19% Response assessment PD 20% (Median) duration assessments OS 9 months Assessment, Analysis, and Discussion Completion Pharmacokinetics / Pharmacodynamics Investigator s Assessment Study completed Not Collected Active and should be pursued further Discussion The standard treatment for non-small cell lung cell cancer (NSCLC) stages IIb and IV is a platinum compound combined with a third-generation cytotoxic agent [2 6]. This study was planned to determine whether, in the first line setting, a platinum compound could be replaced with another cytotoxic agent in the treatment of stage IIIb and IV NSCLC without any increased toxicity.the combination of gemcitabine and pemetrexed (GP) appeared to retain activity, possibly improving the outcome, with more partial responses and longer survival. Tolerability was also better (Fig. 1). The schedule of administration was different, but the doses were chosen so that the dose intensity of gemcitabine should be as similar as possible. The gemcitabine dose intensity was 833 mg/m 2 per week in the gemcitabine and carboplatin (GC) group and 750 mg/m 2 per week in the GP group. This minor dose difference is unlikely to explain any difference between the two arms.
5 The combination of gemcitabine and pemetrexed had shown synergistic effects in cultured cell lines [7, 8] and one phase II study for NSCLC was available at the time of planning this study, showing the feasibility of this treatment[9]. Since then, more studies have been published [10 13]. A combination of pemetrexed 500 mg and gemcitabine 1,500 mg in a biweekly cycle was well tolerated in an escalating study [15] but later proved too toxic for patients aged.70 years [13]. It was better tolerated in anotherstudy in which survival was not as good as in the present study [14].The main difference between that study and ours seems to be a higher incidence of adenocarcinoma in our study. In Sweden today, adenocarcinoma is the most common type of lung cancer, and women have overtaken men in incidence, as found in this study. These tendencies occur today all over the Western world. When this study was planned, the importance of histology for the effect of pemetrexed was not known. It is now generally accepted that its effects are best for nonsquamous NSCLC [15], and the fact that adenocarcinomas were the most common tumor type in our study might be reflected in the better performance of GP. TheresultsintheGCarmarecomparabletotheearlierSwedishstudies[16,17]withoverallsurvivalof8 9months;however, GP has survival that seems superior to earlier published studies with pemetrexed and carboplatin with overall survival of months [10 13] or with pemetrexed and cisplatin with overall survival of 10 months [12]. This indicates that the combination of pemetrexed and gemcitabine should be investigated further. In conclusion, this study shows that pemetrexed can be substituted for a platinum compound in the first-line treatment of NSCLC without increasing the side effects. A trend toward better survival was observed with the GP combination, but the study was not powered to show this. Further studies with this combination seem warranted. References 1. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: Chemotherapy in non-small cell lung cancer: A meta-analysis fron 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311: Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update J Clin Oncol 2004;22: Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346: Le Chevalier T, Scagliotti G, Natale R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005;47: Zatlukal P, Novakova L, Peyruzelka L et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003;41: Tesei A, Ricotti L, De Paola F et al. In vitro schedule dependent interactions between the multitargeted antifolate LY and gemcitabine in human colon adenocarcinoma cells. Clin Cancer Res 2002;8: Giovannetti E, Mey V, Danesi R et al. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004;10: Adjei AA, Nair S, Reuter N et al. Pemetrexed/gemcitabine as front line therapy for advanced NSCLC: A randomized, phase II trial of three schedules. J Clin Oncol 2004;22(suppl):7070a. 10. Monnerat C, Le Chevalier T, Kelly K et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004;10: Adjei AA. Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 2006;17(suppl 5):v29 v Dudek AZ, Larson T, McCleod MJ et al. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3: Sequist LV, Fidias P, Heist RS et al. Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer. J Thorac Oncol 2009;4: Spigel DR, Hainsworth JD, Barton JH et al. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2010;5: Scagliotti G, Brodowicz T, Shepherd FA et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6: Sederholm C, Hillerdal G, Lamberg K et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:
6 17. Hillerdal G, Sederholm C, Andersson K. Randomized phase II study of gemcitabine and carboplatin 1/- sequential docetaxel in non-small cell lung cancer. Lung Cancer 2011;71: Figures and Tables Figure 1. Actual survival in the two arms. Abbreviations: GC, gemcitabine and carboplatin; GP, gemcitabine and pemetrexed. Table 1. Basic findings Characteristic GC GP n Age, years, median (range) 66.7 (54 84) 67.4 (47 84) Female/male, % 57/43 54/46 Pack years Never smokers, % Adenocarcinoma, % Low differentiated/large cell, % 10 7 Squamous cell, % Abbreviations: GC, gemcitabine and carboplatin; GP, gemcitabine and pemetrexed. Table 2. Side effects Event GC GP Side effects grade 3 (mainly lecopenia),% Lowered doses (mainly lecopenia), % Stopped treatment (mainly progressive disease), % Abbreviations: GC, gemcitabine and carboplatin; GP, gemcitabine and pemetrexed.
7 Table 3. Nonhematological toxicity Toxicity GC GP Fatigue grade Total Nausea grade Total Rash grade Total 4 19 GI grade Total 9 13 Abbreviations: GC, gemcitabine and carboplatin; GI, gastrointestinal; GP, gemcitabine and pemetrexed. Click here to access other published clinical trials.
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationDisclosures Amichai Baron: Ora Bio Ltd. (RF, E). The other authors indicated no financial relationships.
Overview First Published Online March 16, 2015 DOI: 10.1634/theoncologist.2014-0424 Title: A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationLung cancer is the leading cause of cancer mortality in both
ORIGINAL ARTICLE Chemotherapy in Patients 80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and Paul J. Hesketh, MD,* Rogerio C. Lilenbaum, MD, Kari Chansky, MS, Afshin Dowlati,
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationSystemic chemotherapy improves both survival and quality
ORIGINAL ARTICLE Treatment of Elderly Non small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Suresh Ramalingam,
More informationLung cancer is the leading cause of cancer-related death in
ORIGINAL ARTICLE A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Nonsmall Cell Lung Cancer Christelle Clément-Duchêne, MD,* Yelena Krupitskaya,* Kristen
More informationApproximately 50% of patients diagnosed with non-small
ORIGINAL ARTICLE A Randomized Phase II Trial of Pemetrexed/Gemcitabine/ Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationLung cancer is the leading cause of cancer death in the
ORIGINAL ARTICLE A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly Yuh-Min Chen, MD, PhD,* Reury-Perng Perng,
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationWelcome to today s presentation titled In Advanced Non Small Cell Lung Cancer: The Evidence-Based Rationale for ALIMTA on Clinical Pathways.
Welcome to today s presentation titled In Advanced Non Small Cell Lung Cancer: The Evidence-Based Rationale for ALIMTA on Clinical Pathways. This presentation features topics designed to raise awareness
More informationALIMTA First Chemotherapy Approved As Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. For Immediate Release Contact: Amy Sousa, Lilly Neil Hochman, TogoRun 317-276-8478 (office) 212-453-2067 (office) 317-997-1481
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationOverview of Standard Phase II Design Issues
Overview of Standard Phase II Design Issues Elizabeth Garrett-Mayer, PhD Associate Professor Hollings Cancer Center Medical University of South Carolina Primary Phase II Goals Phase II study aka Safety
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationAuthor(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)
Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue
More informationPemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer
Clin Oncol Cancer Res (2011) 8: 235 241 235 DOI 10.1007/s11805-011-0587-3 Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationReport on New Patented Drugs Iressa
Report on New Patented Drugs Iressa Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Price Guidelines,
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationKey Words. Erlotinib Non-small cell lung cancer Maintenance treatment
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationBortezomib (PS-341), a potent and selective proteasome
ORIGINAL ARTICLE Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer Angela M. Davies, MD,* Cheryl Ho, MD, Alex S.
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationOUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
ISSN: 1312-773X (Online) http://dx.doi.org/10.5272/jimab.2013193.481 Journal of IMAB - Annual Proceeding (Scientific Papers) 2013, vol. 19, issue 3 OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE
More informationKey Words. Bevacizumab Avastin Nonsquamous Non-small cell lung cancer First-line Advanced/metastatic disease
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Bevacizumab (Avastin ) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell
More informationRESEARCH ARTICLE. Ying Fang, Li Wang, Guo-Hao Xia, Mei-Qi Shi* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage Ⅲ/IV Squamous Non-small Cell Lung Cancer Ying Fang, Li Wang,
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationGemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Clinical Medicine Insights: Oncology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationGlobally, lung cancer is the most common cause of cancer
ORIGINAL ARTICLE Survival without Common Criteria Grade 3/4 for Compared with in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis Jean-Louis Pujol,
More informationPlatinum-based doublet chemotherapy is the standard firstline
ORIGINAL ARTICLE A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel, MD,* John D. Hainsworth, MD,*
More informationThe treatment of patients with metastatic non-small cell
ORIGINAL ARTICLE Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC) A Phase I/II Study from the Hoosier Oncology Group Shadia Jalal, MD,* David Waterhouse, MD, Martin
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationLong term survival in EGFR positive NSCLC patient. Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV
Long term survival in EGFR positive NSCLC patient Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV Medical history and diagnosis Male, caucasian 60 years old Former smoker (stop > 15 years)
More informationPlatinum-containing first-line chemotherapy has improved
Original Article PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationONCOLOGY LETTERS 5: , 2013
ONCOLOGY LETTERS 5: 761-767, 2013 Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer TOSHIKI
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationOncologist. The. ASCO 2000: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. ABSTRACT
The Oncologist ASCO 2000: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Key Words. Small cell lung cancer Non-small
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationMaintenance therapies in advanced non-small-cell lung cancer
Review Maintenance therapies in advanced non-small-cell lung cancer Advanced non-small-cell lung cancer is treated with upfront platinum doublet chemotherapy, which produces moderate survival improvements.
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationPemetrexed in the maintenance treatment of advanced non-small cell lung cancer
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SINGLE TECHNOLOGY APPRAISAL (STA) Pemetrexed in the maintenance treatment of advanced non-small cell lung cancer Prepared by Eli Lilly and Company
More informationdoi: /theoncologist originally published online February 3, 2009
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line? Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Maria Anna
More informationOncologist. The. Cancer Treatment Reports: Early Drug Trials
The Oncologist Cancer Treatment Reports: Early Drug Trials A Phase I Study of Weekly Topotecan in Combination with Pemetrexed in Patients with Advanced Malignancies HOWARD A. BURRIS III, a,b JEFFREY R.
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationThree-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
Original article Annals of Oncology 13: 1080 1086, 2002 DOI: 10.1093/annonc/mdf186 Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study H. Soto Parra
More informationCâncer de Pulmão Não Pequenas Células
Câncer de Pulmão Não Pequenas Células Carboplatina + Paclitaxel Paclitaxel: 200mg/m 2 IV D1 Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos Ref. (1) Vinorelbina + Cisplatina Vinorelbina: 25mg/m 2 IV
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationSystemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationPublished Ahead of Print on March 3, 2014 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on March 3, 2014 as 10.1200/JCO.2013.52.7804 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2013.52.7804 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationVolunteer for Clinical Research
Volunteer for Clinical Research ABOUT RESOURCES CLINICAL RESEARCH FIND STUDIES Clicking on ABOUT brings to this track of information about Clinical Research Clinical Research Research on human volunteers
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationRESEARCH ARTICLE. Adnan Khosravi 1, Babak Salimi 2, Zahra Esfahani-Monfared 2, Sharareh Seifi 2 *, Hanifeh Mirtavoos-Mahyari 2. Abstract.
DOI:10.22034/APJCP.2018.19.10.2973 Formeta Plus Carboplatin as First-Line Treatment RESEARCH ARTICLE Editorial Process: Submission:05/31/2018 Acceptance:09/10/2018 A Phase IV Efficacy Study of Formeta
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationPralatrexate (FOLOTYN Allos Therapeutics, Inc., Westminster,
ORIGINAL ARTICLE Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer Safety and Efficacy in a Phase 1 Trial Christopher G. Azzoli, MD,* Jyoti
More informationHanrui Chen, Xuewu Huang, Shutang Wang, Xinting Zheng, Jietao Lin, Peng Li, Lizhu Lin
Original Article Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial Hanrui Chen,
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationThe treatment outcome in patients with advanced nonsmall
ORIGINAL ARTICLE Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials Katsuyuki Hotta,
More informationSupplementary Material
1 Supplementary Material 3 Tumour Biol. 4 5 6 VCP Gene Variation Predicts Outcome of Advanced Non-Small-Cell Lung Cancer Platinum-Based Chemotherapy 7 8 9 10 Running head: VCP variation predicts NSCLC
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationHirsh Koyi, 1,2,3 Gunnar Hillerdal, 4 Olov Andersson, 4 Karl-Gustav Kölbeck, 4 Per Liv, 3 and Eva Brandén 1,2,3. 1. Introduction
Lung Cancer International Volume 05, Article ID 37868, 6 pages http://dx.doi.org/0.55/05/37868 Research Article Chemotherapy Treatment of Elderly Patients ( 70 Years) with Non-Small Cell Lung Cancer: A
More information